Market Overview

Abbott's HUMIRA Receives U.S. FDA Approval

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA^® (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.  Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary diseases that comprise inflammatory bowel disease (IBD). 

Posted-In: News FDA

 

Most Popular

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters